3-Amino-3-(6-chloro-pyridin-3-yl)-propionic acid, 95.0%, 1g

(S)-3-((tert-Butoxycarbonyl)amino)-3-(3-fluorophenyl)propanoic acid, 95.0%, 1g

(Z)-N-(PYRIDIN-4-YLMETHYLENE)METHANAMINE OXIDE, 95.0%, 100mg

(R)-2-((tert-Butoxycarbonyl)(ethyl)amino)propanoic acid, 95%, 250mg

2-Bromo-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole, 97%, 5g

3-Bromo-1-methylpyrrolidin-2-one, 97.0%, 5g

3,3-Dimethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride, 95.0%, 250mg

2H-3-Benzazepin-2-one, 3-[3-[[[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-, hydrochloride (1:1), 99%, 250mg

6-Bromo-4-chloro-8-fluoro-quinoline-3-carbonitrile, 97.0%, 100mg

Methylbis(2-pyridylmethyl)amine>98.0%(GC)5g

6-Bromohex-1-yne, 95%, 10g

1-(3-Chloro-4-methylphenyl)ethan-1-amine, 97%, 100mg

Potassium formate, min. 98%, for synthesis, 250 g, plastic packaging.